HBeAg阴性慢性乙型肝炎患者长期核苷(酸)类似物治疗停药后的随访及管理

摘要/Abstract

摘要： 乙型肝炎病毒(HBV)感染在全球范围内广泛流行,研究表明,HBeAg阴性慢性乙型肝炎(CHB)患者停止核苷(酸)类似物(NAs)治疗虽然有很多益处,但是其风险不确定性高,很多患者会出现临床复发甚至需要肝移植或者死亡。临床研究表明,HBeAg阴性CHB患者停用NAs后还需加强治疗后管理,2022版中国CHB防治指南建议对HBeAg阴性但可检测到HBV DNA的患者进行抗病毒治疗。根据各国实际情况,国内外对于HBeAg阴性CHB患者停药指征的指南尚不统一.本文根据各国CHB防治指南以及针对HBsAg、HBV DNA或者HBV DNA 等生物标志物联合评判HBeAg阴性CHB患者是否在停止NAs治疗后需要药物再治疗研究进行综述,为HBeAg阴性CHB治疗和预后管理提供理论支持。

关键词: 慢性乙型肝炎, HBeAg阴性, 核苷(酸)类似物, 停药指南

余姣, 万谟彬. HBeAg阴性慢性乙型肝炎患者长期核苷(酸)类似物治疗停药后的随访及管理[J]. 肝脏, 2024, 29(3): 263-265.

参考文献

[1] Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021. Accountability for the global health sector strategies 2016-2021.
[2] Cui F, Shen L, Li L, et al. Prevention of chronic hepatitis B after 3 decades of escalating vaccination policy, China[J]. Emerg Infect Dis, 2017, 23(5): 765-772.
[3] Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study[J]. Lancet Gastroenterol Hepatol, 2018,3(6):383-403.
[4] Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update[J]. Hepatol Int,2016,10(1):1-98
[5] European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017,67(2):370-398.
[6] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology 2018;67(4):1560-1599
[7] 中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J].中华肝脏病杂志, 2022, 30(12): 1309-1331
[8] Thompson A, Jackson K, Bonanzinga S, et al. Baseline serum HBV RNA is associated with the risk of hepatitis flare after stopping nucleoside analog therapy in HBeAg-negative participants[J]. Hepatol Commun, 2023,7(8):e0188.
[9] Islam M, Kumar K, Sevak J, et al. Immune drivers of HBsAg loss in HBeAg-negative CHB patients after stopping nucleotide analog and administration of Peg-IFN[J]. Hepatol Commun,2023,7(5):e0098.
[10] Wübbolding M, Lopez Alfonso J, Lin C, et al. Pilot Study Using Machine Learning to Identify Immune Profiles for the Prediction of Early Virological Relapse After Stopping Nucleos(t)ide Analogues in HBeAg-Negative CHB[J]. Hepatol Commun,2021;5(1):97-111.
[11] Hadziyannis S, Sevastianos V, Rapti I, et al. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir[J]. Gastroenterology, 2012,143(3):629-636.e1.
[12] Hirode G, Choi H, Chen C, et al. Off-Therapy Response After Nucleos(t)ide Analogue Withdrawal in Patients With Chronic Hepatitis B: An International, Multicenter, Multiethnic Cohort (RETRACT-B Study)[J]. Gastroenterology,2022,162(3):757-71.e4.
[13] Sonneveld M, Park J, Kaewdech A, et al. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)[J]. Clin Gastroenterol Hepatol,2022 ,20(4):e784-e793.
[14] Hall S, Burns G, Anagnostou D, et al. Stopping nucleot(s)ide analogues in non-cirrhotic HBeAg-negative chronic hepatitis B patients: HBsAg loss at 96 weeks is associated with low baseline HBsAg levels[J]. Aliment Pharmacol Ther,2022,56(2):310-320.
[15] Chang M, Liaw Y, Hadziyannis S. Systematic review: cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B[J]. Aliment Pharmacol Ther,2015,42(3):243-257.
[16] Papatheodoridis G, Vlachogiannakos I, Cholongitas E, et al. Discontinuation of oral antivirals in chronic hepatitis B: A systematic review[J]. Hepatology,2016,63:1481-1492.
[17] Yao Y, Zhang J, Li X, et al. Systematic review: Clinical outcomes of discontinuation of oral antivirals in hepatitis B-related liver cirrhosis[J]. Front Public Health,2022,10:1037527.
[18] Butt S, Satnarine T, Ratna P, et al. A Systematic Review on Current Trends in the Treatment of Chronic Hepatitis B to Predict Disease Remission and Relapse[J]. Cureus,2022,14:e32247.
[19] Hall S, Vogrin S, Wawryk O, et al. Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis[J]. Gut ,2022,71(8):1629-1641.
[20] Agarwal K, Lok J, Carey I, et al. A case of HBV-induced liver failure in the REEF-2 phase II trial: Implications for finite treatment strategies in HBV 'cure'[J]. J Hepatol, 2022,77(1):245-248.
[21] Liu Y, Jia M, Wu S, et al. Predictors of relapse after cessation of nucleos(t)ide analog treatment in HBeAg-negative chronic hepatitis B patients: A meta-analysis[J]. Int J Infect Dis,2019,86:201-207.
[22] Liu J, Li T, Zhang L, et al. The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogues Cessation Among Asian Patients With Chronic Hepatitis B: A Systematic Review[J]. Hepatology,2019,70(3):1045-1055.
[23] Berg T, Lampertico P. The times they are a-changing -A refined proposal for finite HBV nucleos(t)ide analogue therapy[J]. J Hepatol,2021,75(2):474-480.